Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Amnah Alhanaee: Are We Over-Treating Portal Vein Thrombosis in Cirrhosis?
Mar 29, 2026, 16:00

Amnah Alhanaee: Are We Over-Treating Portal Vein Thrombosis in Cirrhosis?

Amnah Alhanaee, Gastroenterologist and Hepatologist at Burjeel Hospital, shared a post on LinkedIn:

“Are we over-treating portal vein thrombosis in cirrhosis?

At the Baveno VIII Consensus Workshop, this question stood out more than any data.

I presented a clinical pathway focused on real-world decision-making in PVT—not just theory, but what actually happens at the bedside.

One key message:

Not all PVT requires anticoagulation

Yet in practice, many patients are automatically anticoagulated… without fully considering:

  • The underlying phenotype
  • Transplant candidacy
  • Extent of thrombosis (e.g., SMV involvement)
  • Timing and need for escalation

The real challenge is not treatment — it’s decision-making under uncertainty.

What we need is:

  • Structured MDT pathways
  • Early and dynamic reassessment
  • Clear triggers for escalation

And most importantly:

  • TIPS should be considered a strategy—not a rescue.

Meetings like Baveno highlight an important gap:

  • Guidelines exist—but real-world decision-making still varies widely.

Curious to hear from colleagues:

  • Do you anticoagulate all PVT in cirrhosis?
  • Or follow a more selective, phenotype-driven approach?”

Amnah Alhanaee: Are We Over-Treating Portal Vein Thrombosis in Cirrhosis?

Stay updated with Hemostasis Today.

 

Amnah Alhanaee Cirrhosis Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine portal vein thrombosis PVT thrombosis
NewsFeed